Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020115548 - RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY

Publication Number WO/2020/115548
Publication Date 11.06.2020
International Application No. PCT/IB2019/001292
International Filing Date 03.12.2019
IPC
A61K 51/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
10Antibodies or immunoglobulins; Fragments thereof
A61K 31/502 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
502ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5377 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
C07D 237/32 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
237Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
26condensed with carbocyclic rings or ring systems
30Phthalazines
32with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Applicants
  • FUSION PHARMACEUTICALS INC. [CA]/[CA]
  • BURAK, Eric, Steven [US]/[CA] (US)
Inventors
  • BURAK, Eric, Steven
  • FORBES, John, Richard
  • HU, Meiduo
  • VALLIANT, John, Fitzmaurice
Agents
  • GAUVREAU, Julie
Priority Data
62/774,84703.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY
(FR) POLYTHÉRAPIE ASSOCIANT DES RADIOIMMUNOCONJUGUÉS ET DES INHIBITEURS DE RÉPARATION DES DOMMAGES À L'ADN
Abstract
(EN)
Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
(FR)
L'invention concerne des polythérapies comprenant l'administration de radioimmunoconjugués et d'inhibiteurs de la réponse aux dommages à l'ADN.
Latest bibliographic data on file with the International Bureau